Nexstim logo

Nexstim to present at 3rd Neurotech Investing & Partnering Summit in Geneva

07 September 2015

Nexstim Plc (NXTMH:HEX, NXTMS:STO), a medical technology company aiming to improve rehabilitation for stroke patients through the use of non-invasive brain stimulation, announces today that Chief Executive Officer, Janne Huhtala, will be presenting at the Neurotech Investing & Partnering conference in Geneva at 11:30 CEST on Wednesday 9 September 2015.

The conference is a global forum where investors, executives, entrepreneurs, scientists and others involved in the development of new treatments and diagnostics for the brain and nervous system come together to shape the future of their organisation and the industry. For information about the conference, please visit www.neurotechconfeurope.com. The Company’s presentation will be made available at www.nexstim.com following the conference.

For further information please visit www.nexstim.com or contact:

Nexstim      
Janne Huhtala, Chief Executive Officer              
+358 (0)40 8615046                                                                                                                                                                                                                                        

UB Capital Oy (Certified Adviser)       
+358 (0)9 2538 0225                                                                                                              

Consilium Strategic Communications      
Mary-Jane Elliott / Ivar Milligan / Laura Thornton   
+44 (0)20 3709 5700
nexstim@consilium-comms.com                                                                                                                                                                                 

About Nexstim Plc
Nexstim is a medical technology company aiming to improve rehabilitation for stroke patients. Nexstim has pioneered its technology in brain diagnostics with the Navigated Brain Stimulation (NBS) system as the first and only FDA-cleared and CE-marked navigated Transcranial Magnetic Stimulation (nTMS) device for pre-surgical mapping of the motor and speech cortices. Based on the same technology platform, the company has developed a device for stroke therapy called Navigated Brain Therapy (NBT®). In H1 2014, Nexstim initiated a two-year pivotal Phase III study at 12 sites in the US aiming to demonstrate the effectiveness of NBT® and gain FDA clearance for commercialisation in post-acute stroke therapy in the US. Nexstim's shares are listed on Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit www.nexstim.com.

 

Back to Press Releases

Sorry, there are no fact sheets available. Please check back soon.

Follow us

linkedin

Twitter
YouTube